Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01439880 · ClinicalTrials.gov registry record · Phase 2

Open Label Study of Long Term Evaluation Against LDL-C Trial

A Phase 2 study, sponsored by Amgen.

Completed
Registry status
Phase 2
Development phase
1,324
Enrollment target

NCT01439880: Completed Phase 2 study, sponsored by Amgen.

NCT01439880 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 1,324 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (895% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01439880, a Phase 2 study, has completed, sponsored by Amgen.

COMPLETED
Registry status
Phase 2
Development phase
1,324 participants
Enrollment target

Study Summary

The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in adults with hypercholesterolemia.

Primary Outcome

Adverse event (AE) severity assessments were made using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) grading, version 4.03, where grade 1 = mild AE, grade 2 = moderate AE, Grade 3 = severe AE, grade 4 = life-threatening AE and Grade 5 = death due to AE.

Interventions

  • OTHER Standard of care
  • BIOLOGICAL Evolocumab

Trial Details

FieldValue
Enrollment Target 1,324 participants
Start Date 2011-10-07
Est. Completion 2018-06-20
Phase Phase 2
Amgen

558 total trials

What the finished NCT01439880 record still lists

NCT01439880 is an interventional study that assigns participants to a tested intervention. Its 1,324 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (895% higher).

The record links to 0 conditions, and to 2 interventions - of which Standard of care is the first listed.

NCT01439880 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01439880 about?

NCT01439880 is a clinical study titled "Open Label Study of Long Term Evaluation Against LDL-C Trial". The primary clinical hypothesis is that long-term exposure of evolocumab (AMG 145) will be safe and well tolerated in adults with hypercholesterolemia.

What is the current status of trial NCT01439880?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,324 participants. The study started on 2011-10-07. Estimated completion is 2018-06-20.

What interventions are being tested in trial NCT01439880?

The interventions under investigation include: Standard of care (OTHER), Evolocumab (BIOLOGICAL).

Who is sponsoring clinical trial NCT01439880?

This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01439880's enrollment target sits among peer trials

1,324 13th of 2000 higher than 1,988 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05097287 · 1,324 participants · Phase 4

    Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma

  • NCT05889182 · 1,328 participants · Phase 3

    A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

  • NCT06557005 · 1,320 participants · NA

    Facilitated Transitions From Postpartum to Primary Care Coordination for People With Chronic Conditions

  • NCT07213908 · 1,320 participants · NA

    Comparing Two School-Based Sleep Health Interventions To Promote Sleep Quality in Youth

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT01439880, the US trial registry maintained by the National Library of Medicine. NCT01439880 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.